Moleculin Biotech, Inc Appoints Hongbo Zhai to its Science Advisory Board
March 10, 2020 at 05:02 pm IST
Share
On March 10, 2020, Moleculin Biotech, Inc. announced that Dr. Hongbo Zhai, former Senior Faculty and Supervisor of Postdoctoral Fellows at University of California San Francisco, has joined Moleculin’s Science Advisory Board. As a former board-certified dermatologist in China, Dr. Hongbo Zhai has extensive experience with Chinese regulatory authorities including the CFDA and the Ministry of Public Health. Dr. Zhai has contributed to the development of products in collaboration with global Fortune 500 companies such as Procter & Gamble, Pfizer, Johnson & Johnson, 3M Pharmaceuticals, and L’OREAL and has published more than 120 scientific articles in his research areas.
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company. The Company has a pipeline of clinical programs for the treatment of tumors and viruses. It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).